| Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. | |
| | |
MedLine Citation:
|
PMID: 23037712 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries. METHODS: We analysed outcome among all patients (n=99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome. RESULTS: The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n=55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a non-bevacizumab regimen (n=44; P=0.014). Bevacizumab continuation was an independent predictor of improved OS (hazard ratio=0.64; P=0.04). CONCLUSION: The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial. |
| | |
Authors:
|
D A Reardon; J E Herndon; K B Peters; A Desjardins; A Coan; E Lou; A L Sumrall; S Turner; E S Lipp; S Sathornsumetee; J N Rich; J H Sampson; A H Friedman; S T Boulton; D D Bigner; H S Friedman; J J Vredenburgh |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural Date: 2012-10-04 |
Journal Detail:
|
Title: British journal of cancer Volume: 107 ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-24 Completed Date: 2013-03-21 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: England |
Other Details:
|
Languages: eng Pagination: 1481-7 Citation Subset: IM |
Affiliation:
|
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA. dreardon3@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angiogenesis Inhibitors / administration & dosage*, adverse effects Antibodies, Monoclonal, Humanized / administration & dosage*, adverse effects Brain Neoplasms / drug therapy* Disease Progression Drug Administration Schedule Glioblastoma / drug therapy* Humans Middle Aged Neoplasm Recurrence, Local / drug therapy* Retrospective Studies Survival Analysis Treatment Outcome Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
5 R37 CA11898/CA/NCI NIH HHS; 5P50-NS-20023/NS/NINDS NIH HHS; MO1 RR 30/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Monogenic diabetes mellitus due to defects in insulin secretion.
Next Document: The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma.